about
Hemopressin is an inverse agonist of CB1 cannabinoid receptorsEmerging adenosine receptor agonistsPainful diabetic neuropathy: advantage of novel drugs over old drugs?2020 Foresight: Envisioning Therapeutic Innovations for Pain.2,3-Dihydro-1-benzofuran derivatives as a series of potent selective cannabinoid receptor 2 agonists: design, synthesis, and binding mode prediction through ligand-steered modeling.Combination of alpha lipoic acid and superoxide dismutase leads to physiological and symptomatic improvements in diabetic neuropathyMoving from an averaged to specific view of spinal cord pain processing circuits.Current challenges and future prospects in management of neuropathic pain.Translational pain research: achievements and challengesSynthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain.Current approaches with the glutamatergic system as targets in the treatment of neuropathic pain.Analgesic effects of ketamine infusion therapy in korean patients with neuropathic pain: A 2-week, open-label, uncontrolled study.Ion channel blockers for the treatment of neuropathic pain.Recent advances in the pharmaceutical management of pain.Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system.Why are antiepileptic drugs used for nonepileptic conditions?Emerging drugs for neuropathic pain.Effect of chrysin on nociception in formalin test and serum levels of noradrenalin and corticosterone in rats.Analgesic Effect of Indian Gooseberry (Emblica officinalis Fruit) Extracts on Postoperative and Neuropathic Pain in Rats.Gabapentin reverses central pain sensitization following a collagenase-induced intrathalamic hemorrhage in ratsChallenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.Cost-effectiveness of pregabalin: a UK perspective.TRPV1 mediates the uterine capsaicin-induced NMDA NR2B-dependent cross-organ reflex sensitization in anesthetized rats.Role of A3 adenosine receptor in diabetic neuropathy.
P2860
Q24683759-A80A3A7F-902F-432C-B1FB-03A15D7D88C1Q28249111-8C518CF0-54F2-4AEC-A3A7-1C42D6FB89C5Q33610824-585C1BD5-9DAC-42ED-9E86-B4C14916229FQ35069143-646AB2C6-5808-4F94-8260-D99E51BA5D16Q35685828-A0C09E38-61B5-4CB5-A2AD-656567A29847Q36649993-0EA1F4C6-B06B-443E-8EF7-DA589777760CQ36849109-DC6FA0A3-3CF3-4E40-90F8-0313010AC635Q37318165-EC01B41B-F81E-4889-AB1C-60D44819B5A2Q37376539-4F9E8A04-6B35-41C0-B350-AE22FA799186Q37381216-38AB58DB-A304-40AA-9771-A3680B567D77Q37523991-341BEAB1-4064-4702-A59F-3CE2C18C162FQ37667211-28187A23-4EBE-428F-B995-572AF77BABD3Q37855929-22FC4A48-41F8-4E1A-8E46-4F35385D96B0Q37960192-AC98EDCC-0F8F-4BD6-A62A-3341C5CF7EE2Q38056397-ED0AAD72-08BD-4BB7-A7C4-B378875AFBC1Q38059891-0CC615BF-07FD-4E72-BF7D-DE9A7841E776Q38209093-5F75D9C5-A5FD-4FEB-94C8-7820B45AE0B8Q39779943-1F320ABF-C01F-4A4A-85AA-51827F56F942Q39948914-C7BE3936-DDA6-473A-87F9-94BAED30D2CAQ41893886-66005C1A-CA58-4DD9-94EA-9339208E3E81Q42359116-F638B60E-2080-435E-90C8-F379369AA245Q43042808-BDC98FAA-D4E5-4039-8888-F53FCE491905Q46480083-94D1737B-04E8-4D6B-B941-D817D0FAA65DQ51695247-7653DBCB-11A6-4A47-A245-3E1EE91542AB
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Emerging drugs in neuropathic pain.
@ast
Emerging drugs in neuropathic pain.
@en
type
label
Emerging drugs in neuropathic pain.
@ast
Emerging drugs in neuropathic pain.
@en
prefLabel
Emerging drugs in neuropathic pain.
@ast
Emerging drugs in neuropathic pain.
@en
P2860
P1476
Emerging drugs in neuropathic pain.
@en
P2093
Ian Gilron
Terence J Coderre
P2860
P304
P356
10.1517/14728214.12.1.113
P407
P577
2007-03-01T00:00:00Z